Pure Global
NCT06411015

Prognostic Evaluation Prediction Model Survival Spinal Epidural Metastases

Prognostic Evaluation of Prediction Model Survival Spinal Epidural Metastases
Radboud University Medical Center·ClinicalTrials.govCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Predictive Cancer Model
Study type
Observational
Sponsor & location
Primary sponsor
Radboud University Medical Center
Location
Nijmegen, Netherlands
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2021
End date
May 01, 2024
Enrollment
428 participants
Primary outcome

survival after diagnosis of spinal metastasis

Summary

Patients with symptomatic spinal metatstasis will be prosepectively included in a database
 after theu signes informed consent. Minimally six months after inclusion the survival status
 is analyzed. These are correlated with factors that are used in an earlier develloped
 prediction model

ICD-10 classifications
Personal history of chemotherapy for neoplastic diseaseMalignant neoplasm, primary site unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unknown, so stated
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06411015
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06411015 through Pure Global AI's free database. This phase not specified trial is sponsored by Radboud University Medical Center and is currently Completed. The study focuses on Predictive Cancer Model. Target enrollment is 428 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.